Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Convertible Debt (2020 - 2025)

Historic Convertible Debt for Collegium Pharmaceutical (COLL) over the last 6 years, with Q3 2025 value amounting to $238.0 million.

  • Collegium Pharmaceutical's Convertible Debt rose 43.86% to $238.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.0 million, marking a year-over-year increase of 43.86%. This contributed to the annual value of $237.2 million for FY2024, which is 951.95% down from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Convertible Debt is $238.0 million, which was up 43.86% from $237.7 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Convertible Debt's 5-year high stood at $262.4 million during Q1 2024, with a 5-year trough of $26.4 million in Q1 2022.
  • For the 5-year period, Collegium Pharmaceutical's Convertible Debt averaged around $196.8 million, with its median value being $236.9 million (2024).
  • Per our database at Business Quant, Collegium Pharmaceutical's Convertible Debt plummeted by 8108.21% in 2022 and then skyrocketed by 89135.48% in 2023.
  • Collegium Pharmaceutical's Convertible Debt (Quarter) stood at $140.0 million in 2021, then rose by 0.65% to $140.9 million in 2022, then surged by 86.07% to $262.1 million in 2023, then decreased by 9.52% to $237.2 million in 2024, then grew by 0.33% to $238.0 million in 2025.
  • Its last three reported values are $238.0 million in Q3 2025, $237.7 million for Q2 2025, and $237.4 million during Q1 2025.